Annals of Surgical Oncology

, Volume 26, Supplement 3, pp 853–854 | Cite as

ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma

  • Hao LongEmail author
  • Di-Han Liu
ASO Author Reflections



Hao Long and Di-Han Liu have no conflicts of interest to disclose.


  1. 1.
    Lynch T, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.CrossRefGoogle Scholar
  2. 2.
    Liu DH, Zhao ZR, Lin YB, et al. Prognostic Effect of TP53 and PKD Co-mutations in patients with resected epidermal growth factor receptor-mutated lung adenocarcinoma. Ann Surg Oncol. 2019;26:1934–41.CrossRefGoogle Scholar
  3. 3.
    Halvorsen A, Silwal-Pandit L, Meza-Zepeda L, et al. TP53 Mutation spectrum in smokers and never smoking lung cancer patients. Front Genet. 2016;7:85.CrossRefGoogle Scholar
  4. 4.
    Shepherd F, Lacas B, Le Teuff G, et al. Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2017;35(18):2018–27.CrossRefGoogle Scholar
  5. 5.
    Azoitei N, Cobbaut M, Becher A, et al. Protein kinase D2: a versatile player in cancer biology. Oncogene. 2018;37(10):1263–78.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Thoracic Surgery, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineSun Yat-Sen University Cancer CenterGuangzhouChina
  2. 2.Lung Cancer Research CenterSun Yat-Sen UniversityGuangzhouChina

Personalised recommendations